Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery
- PMID: 36646243
- DOI: 10.1016/j.athoracsur.2023.01.014
Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery
Abstract
Background: Previously, we have demonstrated that the 5-year recurrence-free survival after surgery of pure ground-glass opacity (GGO)-featured lung adenocarcinoma is 100%. This study aimed to reveal the long-term outcomes of these patients 10 years after surgery.
Methods: Lung adenocarcinoma patients who underwent surgery between December 2007 and December 2013 were reviewed. Patients with pure GGO-featured lung adenocarcinoma were enrolled. Postoperative survival and the risk of developing second primary lung cancer were analyzed.
Results: Overall, 308 cases of pure GGO-featured lung adenocarcinomas were included. Of these patients, 226 (73.4%) were female, 268 (87.0%) were nonsmokers, and 187 (60.7%) underwent sublobar resection. The median follow-up period after surgery was 112 months. The 10-year recurrence-free survival rate of these patients was 100%, and 10-year overall survival rate was 96.9%. Both 5-year and 10-year lung cancer-specific survival were 100%. There was no difference in 10-year recurrence-free survival rates between patients who underwent lobectomy or sublobar resection (P = .697). EGFR mutations were detected in 55.6% (84 of 151) of patients who underwent mutational analysis. The risk of developing secondary primary lung cancer for pure GGO-featured lung adenocarcinoma patients at 10 years after resection was 2.4%, and was not correlated with EGFR mutation status (P = .452).
Conclusions: No recurrence was observed in patients with pure GGO-featured lung adenocarcinomas 10 years after surgery, even when pathologically evaluated as invasive adenocarcinoma. Pure GGO can be cured by surgery. Surgery is recommended for the appropriate time window with the view to cure. Our study emphasizes that radiologic pure GGO-featured lung adenocarcinomas should be distinguished from other lung adenocarcinomas.
Copyright © 2023 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Comment in
-
Pure Ground-Glass Opacities: Potential for Surgical Cure in Adenocarcinoma; However Selection Is Key.Ann Thorac Surg. 2023 Aug;116(2):237-238. doi: 10.1016/j.athoracsur.2023.01.034. Epub 2023 Feb 4. Ann Thorac Surg. 2023. PMID: 36746326 No abstract available.
-
Therapeutic strategy for lung adenocarcinoma with pure ground-glass opacity: surgery, radiotherapy, or watchful waiting?J Thorac Dis. 2024 Jan 30;16(1):804-806. doi: 10.21037/jtd-23-1633. Epub 2024 Jan 15. J Thorac Dis. 2024. PMID: 38410555 Free PMC article. No abstract available.
-
Not all that glitters is gold.J Thorac Dis. 2024 Apr 30;16(4):2681-2683. doi: 10.21037/jtd-24-38. Epub 2024 Apr 12. J Thorac Dis. 2024. PMID: 38738223 Free PMC article. No abstract available.
-
Pure ground-glass opacity of the lung: making the case for a lasting cure.J Thorac Dis. 2024 Apr 30;16(4):2684-2686. doi: 10.21037/jtd-23-1706. Epub 2024 Apr 11. J Thorac Dis. 2024. PMID: 38738246 Free PMC article. No abstract available.
-
Pure ground-glass opacities (GGO) lung adenocarcinoma: surgical resection is curative.J Thorac Dis. 2024 May 31;16(5):3518-3521. doi: 10.21037/jtd-23-1983. Epub 2024 May 22. J Thorac Dis. 2024. PMID: 38883648 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
